Last checked at 23 Apr 2021 07:00
| 23 April 2021 |
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
2021 Annual General Meeting (AGM)
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Notice of AGM 2021 is now available on the Group's website, www.alliancepharmaceuticals.com
Printed copies of the Notice of AGM have been posted to those shareholders who have opted out of receiving electronic communications from the Group.
The AGM will be held at 10.00am on 19 May 2021 at Alliance's head office, Avonbridge House, Bath Road, Chippenham, Wiltshire SN15 2BB
Important notice re COVID-19 and the 2021 AGM
Due to the ongoing uncertainty relating to COVID-19 and the Government's current guidance, it is intended that the 2021 AGM will be held as a hybrid meeting with an appropriate quorum to transact the business of the meeting alongside a live and interactive broadcast to shareholders.
The health and safety of our shareholders and colleagues remains a priority and as such we strongly urge that all shareholders do not attend the AGM in person this year. Further details of how shareholders can fully take part in the AGM remotely are included in the Notice of AGM.
The Board strongly recommends that shareholders register their votes in advance of the meeting by appointing the Chairman of the AGM as proxy, with their voting instructions. Further details are included in the Notice of AGM.
For further information:
Alliance Pharma plc | + 44 (0)1249 466966 |
Peter Butterfield, Chief Executive Officer |
|
Andrew Franklin, Chief Financial Officer |
|
www.alliancepharma.co.uk |
|
Buchanan | + 44 (0)20 7466 5000 |
Mark Court / Sophie Wills / Hannah Ratcliff |
|
|
|
Numis Securities Limited | + 44 (0)20 7260 1000 |
Nominated Adviser: Freddie Barnfield / Oliver Steele |
|
Corporate Broking: James Black |
|
Investec Bank plc | + 44 (0) 20 7597 5970 |
Corporate Finance: Daniel Adams |
|
Corporate Broking: Patrick Robb |
|
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.
We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com